Literature DB >> 11949946

Autoantibody responses to carbohydrate epitopes in endometriosis.

Grant R Yeaman1, Jane E Collins, Gillian A Lang.   

Abstract

Autoantibody responses to endometrial and serum antigens are a common feature of endometriosis. We have shown that the serum autoantibody response in endometriosis to a number of previously identified antigens, including alpha2-Heremans Schmidt glycoprotein and carbonic anhydrase, is specific for a carbohydrate epitope common to these proteins. Removal of carbohydrate moieties from these antigens resulted in a loss of antibody binding. Antibody reactivity was abolished following adsorption with the lectin jacalin, which specifically binds the Thomsen-Friedenreich (T) antigen (Gal beta1-3GalNAc). Demonstration that the autoantibodies also reacted with other Thomsen-Friedenreich antigen-bearing proteins, such as serum IgA1, hemopexin, and MMP-9, confirmed that this glycotope is involved in the autoantibody response. However, the autoantibody binding requires the presence of at least one sialic acid residue. Thus, the glycotope involved may be a sialylated T antigen. These findings allow us to hypothesize a number of mechanisms whereby the autoimmune response plays a direct role in several aspects of the disease process. The proposed mechanisms take into account the salient endocrine dependency of endometriotic lesions and other aspects of the disease process such as aberrant matrix metalloproteinase function and the ability of endometrial cells to implant at ectopic sites. The anti-T-like response may also be indicative of an underlying genetic defect in glycosylation or in the control of glycosylation by steroid sex hormones. Further characterization of this autoimmune response may prove useful in the development of serum-based diagnostic tests for endometriosis and may lead to the development of therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11949946     DOI: 10.1111/j.1749-6632.2002.tb02778.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

Review 1.  Dioxin may promote inflammation-related development of endometriosis.

Authors:  Kaylon L Bruner-Tran; Grant R Yeaman; Marta A Crispens; Toshio M Igarashi; Kevin G Osteen
Journal:  Fertil Steril       Date:  2008-04-18       Impact factor: 7.329

2.  Binding of galectin-1 (gal-1) to the Thomsen-Friedenreich (TF) antigen on trophoblast cells and inhibition of proliferation of trophoblast tumor cells in vitro by gal-1 or an anti-TF antibody.

Authors:  Udo Jeschke; Uwe Karsten; Irmi Wiest; Sandra Schulze; Christina Kuhn; Klaus Friese; Hermann Walzel
Journal:  Histochem Cell Biol       Date:  2006-04-11       Impact factor: 4.304

Review 3.  Medical management of endometriosis: emerging evidence linking inflammation to disease pathophysiology.

Authors:  K L Bruner-Tran; J L Herington; A J Duleba; H S Taylor; K G Osteen
Journal:  Minerva Ginecol       Date:  2013-04

4.  Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer.

Authors:  Liangdan Tang; Junzheng Yang; Shu-Kay Ng; Noah Rodriguez; Pui-Wah Choi; Allison Vitonis; Kui Wang; Geoffrey J McLachlan; Robert J Caiazzo; Brian C-S Liu; William R Welch; Daniel W Cramer; Ross S Berkowitz; Shu-Wing Ng
Journal:  Eur J Cancer       Date:  2010-01       Impact factor: 9.162

Review 5.  Immunological aspects of endometriosis: a review.

Authors:  Milena Králíčková; Vaclav Vetvicka
Journal:  Ann Transl Med       Date:  2015-07

Review 6.  Glycosylation of matrix metalloproteases and tissue inhibitors: present state, challenges and opportunities.

Authors:  Lise Boon; Estefania Ugarte-Berzal; Jennifer Vandooren; Ghislain Opdenakker
Journal:  Biochem J       Date:  2016-06-01       Impact factor: 3.857

Review 7.  Potential involvement of the immune system in the development of endometriosis.

Authors:  Cleophas M Kyama; Sophie Debrock; Jason M Mwenda; Thomas M D'Hooghe
Journal:  Reprod Biol Endocrinol       Date:  2003-12-02       Impact factor: 5.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.